萤光素 (医用)

Fluorescein
	检查前将萤光素滴剂滴入眼睛
临床资料
读音	FLURE-a-seen
商品名（英语：Drug nomenclature）	Fluorescite, AK-Fluor, BioGlo, others
核准状况	美 DailyMed: Fluorescein;
给药途径	眼药水, 静脉注射, 口服给药
药物类别（英语：Drug class）	医学检验
法律规范状态
法律规范	英：处方药（℞-only） (POM); 美：处方药（℞-only）; 处方药（℞-only）;
识别信息
	IUPAC命名法 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one; ;
化学信息
化学式	C20H12O5
摩尔质量	332.31 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O;
	InChI InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H; Key:GNBHRKFJIUUOQI-UHFFFAOYSA-N;

萤光素用于诊断多种眼部疾病^[3]。当以眼药水或含药纸应用于眼球表面时，有助于检测异物和角膜刮伤等眼部损伤（英语：Eye injury）^[4] ^[5]。当经口服或静脉注射时，用于萤光素血管造影术（英语：Fluorescein angiography）中，评估眼球后部的血管（视网膜）的血流情况^[3] ^[6]。

涂抹在眼球表面时，副作用包括可能短暂的视力模糊和使软性隐形眼镜变色^[7] ^[3]。口服或注射时，副作用包括可能头痛、恶心和皮肤颜色短暂的改变^[3]。过敏反应可能偶尔发生^[3]。荧光素是一种染料，受损的角膜会吸收它，在钴蓝光照射下会呈现绿色^[3]。此外，还有预混利多卡因的版本^[4] ^[8]。

萤光素于 1871 年首次制造^[9]。名列世界卫生组织基本药物标准清单^[10]。

参考文献

^ Fluorescein sodium 100 mg/ml, solution for injection - Summary of Product Characteristics (SmPC). (emc). 16 January 2018 [11 March 2020]. （原始内容存档于28 August 2021）.
^ WHOCC - ATC/DDD Index. www.whocc.no. [12 September 2020]. （原始内容存档于1 July 2021）.
^ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 Duvall, Brian; Kershner, Robert M. Ophthalmic Medications and Pharmacology. SLACK Incorporated. 2006: 29. ISBN 9781556427503. （原始内容存档于2017-01-18）（英语）.
^ ^4.0 ^4.1 British national formulary : BNF 69 69. British Medical Association. 2015: 769, 772. ISBN 9780857111562.
^ Hamilton, Richart. Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2015: 416. ISBN 9781284057560.
^ Anatera 100mg/ml solution for injection - Summary of Product Characteristics (SmPC). (emc). 10 February 2020 [11 March 2020]. （原始内容存档于5 August 2020）.
^ World Health Organization. WHO Model Formulary 2008. World Health Organization. 2009: 314. ISBN 9789241547659.
^ Minims Lidocaine & Fluorescein Summary of Product Characteristics (SmPC) - (emc). (emc). 23 October 2017 [11 March 2020]. （原始内容存档于20 September 2020）.
^ Bartlett, Jimmy D.; Jaanus, Siret D. Clinical Ocular Pharmacology. Elsevier Health Sciences. 2008: 283. ISBN 0750675764. （原始内容存档于2017-01-18）（英语）.
^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

外部链接

Fluorescein. Drug Information Portal. U.S. National Library of Medicine. [11 March 2020]. （原始内容存档于12 August 2020）.
Fluorescein sodium. Drug Information Portal. U.S. National Library of Medicine. [11 March 2020]. （原始内容存档于28 August 2021）.

[Fluorescein_SmPC-1] Fluorescein sodium 100 mg/ml, solution for injection - Summary of Product Characteristics (SmPC). (emc). 16 January 2018 [11 March 2020]. （原始内容存档于28 August 2021）.

[who-2] WHOCC - ATC/DDD Index. www.whocc.no. [12 September 2020]. （原始内容存档于1 July 2021）.

[Du2006-3] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 Duvall, Brian; Kershner, Robert M. Ophthalmic Medications and Pharmacology. SLACK Incorporated. 2006: 29. ISBN 9781556427503. （原始内容存档于2017-01-18）（英语）.

[BNF69-4] 4.0 ^4.1 British national formulary : BNF 69 69. British Medical Association. 2015: 769, 772. ISBN 9780857111562.

[Ric2015-5] Hamilton, Richart. Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2015: 416. ISBN 9781284057560.

[6] Anatera 100mg/ml solution for injection - Summary of Product Characteristics (SmPC). (emc). 10 February 2020 [11 March 2020]. （原始内容存档于5 August 2020）.

[WHO2008-7] World Health Organization. WHO Model Formulary 2008. World Health Organization. 2009: 314. ISBN 9789241547659.

[8] Minims Lidocaine & Fluorescein Summary of Product Characteristics (SmPC) - (emc). (emc). 23 October 2017 [11 March 2020]. （原始内容存档于20 September 2020）.

[9] Bartlett, Jimmy D.; Jaanus, Siret D. Clinical Ocular Pharmacology. Elsevier Health Sciences. 2008: 283. ISBN 0750675764. （原始内容存档于2017-01-18）（英语）.

[WHO21st-10] World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[1]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]